FIH-IO Development of a first-in-class inhibitor of FIH for cancer immunotherapy
- Coordinator
- Asociacion Centro De Investigacion Cooperativa En Biociencias Cic Biogune, Spain
- Runs
- 1 June 2022 to 30 November 2023
- Status
- Finished
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101069333
What the project is doing
In the project's own words, from its summary on CORDIS.
We plan to carry out a valorisation project for a series of novel small molecule inhibitors of Factor Inhibiting HIF (FIH) that we have developed for the treatment of lung cancer, as a next-generation therapeutic approach in the field of immuno-oncology. The valorisation plan will include: clarification of IP rights and strategy, establishing contacts with potential investors and pharma partners, and verification of the potential of start-up creation.
Moreover, valorisation activities will include progression of hits against FIH into a lead optimisation campaign with the aim of designating a candidate drug.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Asociacion Centro De Investigacion Cooperativa En Biociencias Cic Biogune | Derio Vizcaya | Spain | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI